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IMPORTANCE Left atrial fibrosis is prominent in patients with atrial fibrillation (AF). Extensive
atrial tissue fibrosis identified by delayed enhancement magnetic resonance imaging (MRI)
has been associated with poor outcomes of AF catheter ablation.
OBJECTIVE To characterize the feasibility of atrial tissue fibrosis estimation by delayed
enhancement MRI and its association with subsequent AF ablation outcome.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, prospective, observational cohort study of
patients diagnosed with paroxysmal and persistent AF (undergoing their first catheter
ablation) conducted between August 2010 and August 2011 at 15 centers in the United
States, Europe, and Australia. Delayed enhancement MRI images were obtained up to 30
days before ablation.
MAIN OUTCOMES ANDMEASURES Fibrosis quantificationwas performed at a core laboratory
blinded to the participating center, ablation approach, and procedure outcome. Fibrosis
blinded to the treating physicians was categorized as stage 1 (<10% of the atrial wall), 2
(10%-<20%), 3 (20%-<30%), and 4 (30%). Patients were followed up for recurrent
arrhythmia per current guidelines using electrocardiography or ambulatory monitor
recording and results were analyzed at a core laboratory. Cumulative incidence of recurrence
was estimated by stage at days 325 and 475 after a 90-day blanking period (standard time
allowed for arrhythmias related to ablation-induced inflammation to subside) and the risk of
recurrence was estimated (adjusting for 10 demographic and clinical covariates).
RESULTS Atrial tissue fibrosis estimation by delayed enhancementMRIwas successfully
quantified in 272 of 329 enrolled patients (57 patients [17%]were excluded due to poorMRI
quality). Therewere 260patientswhowere followed up after the blanking period (mean [SD]
age of 59.1 [10.7] years, 31.5% female, 64.6%with paroxysmal AF). For recurrent arrhythmia, the
unadjusted overall hazard ratio per 1% increase in left atrial fibrosiswas 1.06 (95%CI, 1.03-1.08;
P < .001). Estimated unadjusted cumulative incidence of recurrent arrhythmia by day 325 for
stage 1 fibrosiswas 15.3% (95%CI, 7.6%-29.6%); stage 2, 32.6% (95%CI, 24.3%-42.9%); stage
3, 45.9% (95%CI, 35.5%-57.5%); and stage 4, 51.1% (95%CI, 32.8%-72.2%) and by day 475was
15.3% (95%CI, 7.6%-29.6%), 35.8% (95%CI, 26.2%-47.6%), 45.9% (95%CI, 35.6%-57.5%), and
69.4% (95%CI, 48.6%-87.7%), respectively. Similar resultswere obtained after covariate
adjustment. The addition of fibrosis to a recurrence predictionmodel that includes traditional
clinical covariates resulted in an improved predictive accuracywith the C statistic increasing from
0.65 to0.69 (risk difference of 0.05; 95%CI, 0.01-0.09).
CONCLUSIONS AND RELEVANCE Among patients with AF undergoing catheter ablation, atrial
tissue fibrosis estimated by delayed enhancement MRI was independently associated with
likelihood of recurrent arrhythmia. The clinical implications of this association warrant further
investigation.
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A trial tissue fibrosis affecting the left atrium is a majordeterminant of the progression of atrial fibrillation(AF)1; thus, amore extensively remodeled atrium rep-
resents the substrate needed for the arrhythmia to persist. A
clear correlation has been shown between AF and the degree
of atrial fibrosis inpostmortemhistological analysis.2 Atrial fi-
brosis is also a major determinant for success of rhythm con-
trol strategies in AF,3,4 including catheter ablation, one of the
most efficacious methods to treat patients with AF.5,6 How-
ever, this knowledge has never been incorporated into treat-
ment plans for patients with different degrees of fibrosis.
Delayedenhancementmagnetic resonance imaging (MRI)
is aneffectivemodality to identify fibroticnonviableventricu-
lar myocardium.7-9 Delayed enhancement MRI has also been
used inpatientswhohaveundergone ablationprocedures10,11
to assess for ablation-induced scarring in the left atrial wall.
More recently,delayedenhancementMRIhasbeenused to im-
age the left atrium prior to AF ablation procedures to esti-
mate the degree of atrial tissue fibrosis. Single-center studies
have shown that extensive fibrosis of the left atrialwall quan-
tified by delayed enhancement MRI is associated with recur-
rent arrhythmia following catheter ablation.12,13 In this study,
wehypothesized that atrial fibrosis estimationbydelayed en-
hancement MRI is feasible in multiple centers, and that it is
associated with ablation outcomes after adjusting for known
covariates.
Methods
Study Design
Delayed-EnhancementMRIDeterminant of SuccessfulRadio-
frequencyCatheterAblationofAtrial Fibrillation (DECAAF) is
a multicenter, prospective, observational cohort study of pa-
tients with AF undergoing catheter ablation. All enrolled pa-
tientswithhistoryofAFandwhowere scheduled for their first
ablation procedure underwent a delayed enhancement MRI
scanof the left atrium. Thedatawere deidentified and sent to
a core processing facility with an image processing team
blinded to theparticipating center, the ablationapproach, and
theprocedureoutcome.Theparticipatingcenterswereblinded
to the delayed enhancement MRI quantification of atrial fi-
brosis and followed their routine protocol for ablation tech-
niques andpatientmanagement. Patient follow-updatawere
collected for at least 1 year after the ablation procedure to as-
sess for maintenance of sinus rhythm or recurrent arrhyth-
mias.
Study Patients
Patients from15centers in6countries across 3 continentswere
enrolled in the DECAAF study. Patients were eligible if they
were scheduled to undergo a first AF ablation procedure per
the recent consensus recommendations.14 All eligible pa-
tientsunderwentadelayedenhancementMRIscanbefore their
ablation procedure. Key exclusion criteria were a contraindi-
cation for delayed enhancement MRI with a full dose of
gadolinium-based contrast agent (with an estimated glomer-
ular filtration rate ≥30mL/min), a previous left atrial ablation
or surgical procedure for the treatmentofAF, andmorbidobe-
sity (body mass index >35 or inability to be placed in an MRI
scanner due to body mass). The full list of inclusion and ex-
clusion criteria appears in the Supplement. All patients pro-
videdwritten informedconsent.The institutional reviewboard
or independent ethics committee at each participating clini-
cal center approved the study.
Magnetic Resonance Imaging
The15participatingcenters fromEurope (8centers), theUnited
States (6 centers), and Australia (1 center) had different de-
grees of expertise in cardiac MRI. Customized pulse se-
quences and imaging protocol for the atrial MRI (Marrek Inc)
were installed on 18 SiemensMRI scanners (Siemens Health-
care).Ninecentersused1.5-Tesla scanners, 5 centersused3-Te-
sla scanners, and 1 center used both 1.5- and 3-Tesla scan-
ners. A detailed description of the atrial imaging protocol is
provided in the Supplement (see Atrial MR Image Acquisi-
tion; eTable 1).
All patients underwent delayed enhancementMRI of the
left atrium less than 30 days prior to the AF ablation proce-
dure. The purpose of theMRI study for DECAAFwas to quan-
tify thedegreeofatrial fibrosis fromdelayedenhancementMRI;
however,otherMRIsequences (suchasanMRangiogram)were
available to provide anatomical guidance prior to and during
the ablation procedure for mapping and image integration.
Delayed EnhancementMRI Assessment
of Left Atrial Fibrosis
Quantification of left atrial fibrosis was obtained using the
methodspreviouslydescribed.12 Todelineate regionsof fibro-
sis in delayed enhancementMRI images prior to ablation, en-
hancementwasdefinedbyan intensity threshold thatwasde-
terminedbyexpert inspection. To assist in this process, initial
visualizationusedavolume-rendering tool inCorview(Marrek)
that allowed the distribution of enhancement in 3D. A cus-
tom transfer function allowed the definition of gradations of
enhancementwhile suppressingbloodandnormal tissue.The
image processing flow is illustrated in Figure 1. Patients were
assigned to 1of4groups (fibrosis stages 1-4) basedon thevolu-
metric percentage of left atrial wall enhancement as illus-
trated in Figure 2.
Clinical Follow-up
The participating centers were required to send patient data
and deidentifiedMR images to the core center online. Aweb-
site was specifically designed to accept all uploaded data, in-
cludingbaselinedemographics andclinical comorbidities, fol-
low-up informationat the specified timepoints for clinicvisits,
and informationfromvisitsduetoanevent (http://www.decaaf
.org). Unique patient identifiers were assigned for data track-
ing and analysis.
Procedural information, drug prescription, and electro-
cardiographic results (12-lead andambulatorymonitors)were
collected at 3, 6, and 12months after the procedure and at any
time available thereafter. The electrocardiogram or ambula-
torymonitor recordings fromclinical follow-upvisitsweresent
to the core center for confirmationof the analysis and theout-
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comes were measured per the guidelines in the recent con-
sensus document.14 Any episode ofAF, atrial flutter, or tachy-
cardia lasting at least 30 seconds and occurring after the 90-
day blanking period was classified as a recurrence.
Statistical Methods
Baselinecharacteristicsweresummarized for260patientswho
were included in the prospective cohort study and for the 69
remaining enrolledparticipantswhowerenot included in the
prospective cohort using means and standard deviations for
continuousvariables and frequencies andpercentages for cat-
egorical factors.Separatesimple linear regressionanalyseswere
performed to relate fibrosis to individual demographic and
clinical covariates. Time to AF recurrence was related to the
individual demographic and clinical covariates using sepa-
rate univariable Cox proportional hazard regression models.
Cox regression analyseswere also performed to relate time
to recurrence of arrhythmia to percent fibrosis without covari-
ate adjustment (model 1) and again after adjusting for the fol-
lowing sets of covariates: clinical center (model 2), clinical cen-
ter,age,andsex(model3);clinicalcenter,age,sex,hypertension,
congestive heart failure,mitral valve disease, and diabetes sta-
tus (model 4); and all covariates in model 4 plus AF type (par-
oxysmalorpersistent), leftatrialvolume,andleftventricularejec-
tion fraction (model 5). The Harrell concordance C statistic for
survival outcomes was used to assess the increase in prognos-
ticaccuracyresultingfromaddingfibrosis totheCoxmodelwith
the final set of covariates.
To test whether the C statistics of 2 models were statisti-
cally significantly different,weused the bootstrapmethod to
derive the standard error of the difference in the C statistics
of the2models andused thenormal z test toderive thePvalue.
TheproportionalityassumptionrequiredbyCoxregressionwas
checked using Schoenfeld residual plots and linear propor-
tionality tests.15 Natural cubic splines with 3 knots were used
to evaluate the shape of the relationship of the log-
transformed hazard for AF recurrence with fibrosis, adjust-
ing for the final set of covariates. Clinical centers with fewer
than 20 patients in the United States and Europe were com-
bined, leaving the 6 largest centers alongwith a combinedUS
centerwitha totalof50patientsandacombinedEuropeancen-
ter with 30 patients.
Figure 1. Process for Quantification of Left Atrial Wall Fibrosis
A Delayed enhancement magnetic resonance imaging analysis B Schematic posterior view of left atrium
Step 1: Acquire axial views of left atrium Step 2: Isolate and identify left atrial wall
Step 3: Quantify enhancement of left atrial wall Step 4: Render 3D model of left atrium
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High-resolution 3D delayed enhancement magnetic resonance imaging (MRI)
scans of the left atrium are acquired (step 1). Epicardial and endocardial borders
are contoured in eachMRI slice to define the left atrial wall segmented region
(step 2). Wall segmentations include the 3D extent of both the left atrial wall
and the antral regions of the pulmonary veins, but exclude themitral valve.
Quantification of fibrosis is based on relative intensity of contrast enhancement
(step 3). The 3Dmodel of the left atrium is rendered from the endocardial (left
atrial cavity) and left atrial wall segmentations, and themaximum enhancement
intensities are projected on the surface of themodel (step 4). Interactive 3D
model at jama.com.
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The completion of the blanking period (ie, 90 days after
ablation) was defined as time zero for all analyses of time to
recurrenceper the consensus statement.14 Theprimary analy-
ses of time to recurrence administratively censored fol-
low-up at day 325 or at the date of last contact for those pa-
tients who were lost to follow-up prior to day 325. The above
analyses were repeated using each patient’s complete fol-
low-up period, including any additional follow-up time after
day 325.We also estimated the absolute risk of recurrence for
the4Utahfibrosis stages (defined in theResults section)atdays
325 and 475 after the blanking period. The unadjusted risks
were estimated using the Kaplan-Meier estimator with 95%
confidence intervals computed on the log-log scale.
The adjusted risks were estimated from a Cox propor-
tionalhazardmodel controlling for covariatesdefined inmodel
5. We used the Breslow estimator to obtain the baseline haz-
ards under the Cox model. Relationships were designated as
statistically significant if the 2-sidedP valuewas less than .05
without adjustment for multiple comparisons. We used SAS
version9.3 (SAS Institute Inc), Stataversion 11 (StataCorp), and
R version 2.11.1 (R Project for Statistical Computing) to per-
form all statistical analyses.
Results
Baseline Characteristics and Ablation
There were 329 patients enrolled in the DECAAF study be-
tween August 2010 and August 2011. Fifty-seven patients
(17.3%) were excluded due to poor MRI quality by consensus
of 3 observers from the core center. Atrial wall fibrosis was
quantified for 272 patients who had preablation delayed en-
hancement MR images of acceptable quality. We lost contact
with 12 of these 272patients during theblankingperiod. Thus,
260 were included in the final cohort for analysis. The mean
(SD) follow-up time prior to day 325 after the blanking period
was 213 (120) days and the total follow-up time was 255 (178)
days.
Table 1 summarizes demographic and clinical character-
istics of this final cohort (n = 260) andof the remaining 69 en-
rolled patients whowere excluded from the final cohort. No-
table characteristicsof theprospective cohort includedamean
(SD)patientageof59.1 (10.7)yearswithamalemajority (68.5%);
64.6% had paroxysmal AF and 63.9% received antiarrhyth-
mic treatment prior to ablation. Ten percent of patients had a
historyof coronaryarterydisease,whereas theprevalencewas
5% for congestive heart failure and 11% for diabetes.
Thepatientsunderwentablationper their institutionalpro-
tocols. Of the final cohort, 16 patients underwent cryobal-
loon ablation (6.2%), and the remainder underwent radiofre-
quency ablation. There were 177 patients (68.1%) who
underwent pulmonary vein isolation alone. Forty-three pa-
tients (16.5%) underwent cavotricuspid isthmus and pulmo-
nary vein isolation ablation. The ablation procedures per-
formed on the patient cohort are summarized in eTable 2 in
the Supplement. At 12months postablation, 53 of 213 patients
(24.9%) were receiving a class 1 or 3 antiarrhythmic drug.
Complications
Therewere complications observed in 5%of the analyzed co-
hortwith6 reported cases of cardiac tamponade, 1 caseof pul-
monary vein narrowing, 1 case of esophageal injury, 1 case of
Figure 2. Four Stages of Left Atrial Tissue Fibrosis Based on 3DDelayed EnhancementMagnetic Resonance Imaging Scans
A Stage 1 (<10% of atrial wall) B Stage 2 (≥10%-<20% of atrial wall)
C Stage 3 (≥20%-<30% of atrial wall) D Stage 4 (≥30% of atrial wall)
Posterior view Anterior view Posterior view Anterior view
Posterior view Anterior view Posterior view Anterior view
Healthy Fibrotic tissue
Representative example from 4 different patients of each stage of left atrial
tissue fibrosis. Normal left atrial wall is displayed in blue; fibrotic changes are in
green and white. Stages 1 through 4 show increasing amounts of fibrosis as a
percentage of the total left atrial wall volume. The pulmonary veins andmitral
valve are shown in gray.
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femoral hematoma, and4casesof femoral arterial–venous fis-
tula. All the patients who experienced complications had re-
covered without long-term sequelae at the conclusion of the
study.
Imaging and Baseline Characteristics
The MRI data were analyzed at the core laboratory for image
quality and for quantification of atrial fibrosis. Based on the
degree of detected fibrosis from delayed enhancement MRI,
4 stageswere defined: stage 1, less than 10%of the atrial wall;
stage2, 10%orgreaterbut less than20%;stage3, 20%orgreater
but less than 30%; and stage 4, 30% or greater. Therewere 49
patients in stage 1 (18.9%), 107 in stage 2 (41.2%), 80 in stage 3
(30.8%), and 24 in stage 4 (9.2%).
ThepercentageofpatientswithparoxysmalAFwas65.3%
for stage 1, 63.6% for stage 2, 61.3% for stage 3, and 79.2% for
stage 4. The selected patient baseline characteristics for each
of the fibrosis disease stages are described in eTable 3 in the
Supplement.Thebivariateanalyses relating fibrosis to theback-
ground covariates revealed that the only factor with a statis-
tically significant association with the amount of atrial fibro-
siswasahistoryofhypertension (eTable4 in theSupplement).
Arrhythmia Recurrence Analysis
The hazard ratios (HRs) relating time of arrhythmia recur-
rence to individual demographic and clinical factors are re-
ported in Table 2. Among these factors, only percent atrial fi-
brosis and history of mitral valve disease (reported cases of
history ofmitral valvediseaseweremainlymitral valve insuf-
ficiency of ≥2 or moderate severity, except 1 reported case of
mitral and tricuspid repair due to mitral valve prolapse) had
statistically significant associations with arrhythmia recur-
rence. For a 1% increase in atrial fibrosis, theHRwas 1.06 (95%
CI, 1.03-1.08; P < .001) compared with patients without a mi-
tral valve disease history. The comparison of those with mi-
tral valve disease history yielded an HR of 3.45 (95% CI, 1.78-
6.68; P < .001).
Thepercent atrial fibrosiswas strongly associatedwith ar-
rhythmia recurrence when age, sex, hypertension, conges-
tive heart failure,mitral valve disease, diabetes, type of atrial
fibrillation (paroxysmal vs persistent), left atrial volume, left
ventricular ejection fraction, andparticipating centerwere ad-
justed for (model 5 in eTable 5 in the Supplement). The over-
all HRwas 1.06 (95%CI, 1.03-1.09; P < .001) per 1% increase in
atrial fibrosis. Figure 3 depicts the relationship of AF recur-
rencewithpercent fibrosis basedon the cubic splinemodel af-
ter controlling for the covariates in model 5.
The relationship was significantly stronger at lower com-
pared with higher levels of fibrosis (test of nonlinearity
P = .03), with the estimated HR per 1% increase in fibrosis
decreasing from 1.15 (95% CI, 1.06-1.25) when fibrosis was
10% of the atrial wall to 1.02 (95% CI, 0.97-1.06) when fibro-
sis was 30%. The Harrell C statistic characterizing the dis-
crimination of time to AF recurrence at 325 days by fibrosis
was 0.65 when atrial fibrosis was considered as a single fac-
tor; however, adding fibrosis to the covariates in model 5
increased the C statistic from 0.65 to 0.69. The difference
between these 2 C statistics was 0.05 (95% CI, 0.01-0.09). A
similar result was found for the entire follow-up period. The
C statistic characterizing discrimination of time to AF recur-
rence for the entire follow-up was 0.65 when atrial fibrosis
was considered as a single factor. The addition of fibrosis to a
recurrence prediction model (model 5) that includes tradi-
tional clinical covariates resulted in an improved predictive
accuracy with the C statistic increasing from 0.64 to 0.69
with a risk difference of 0.05 (95% CI, 0.01-0.09).
Table 3provides estimatesof theabsolute risksof arrhyth-
mia recurrence by stage at days 325 and 475with andwithout
adjustment for the covariates in model 5. The estimated un-
adjusted cumulative incidenceof recurrent arrhythmiabyday
325 for stage 1 fibrosis was 15.3% (95% CI, 7.6%-29.6%); stage
2, 32.6% (95%CI, 24.3%-42.9%); stage 3, 45.9% (95%CI, 35.5%-
57.5%); and stage 4, 51.1% (95% CI, 32.8%-72.2%) and by day
475 was 15.3% (95% CI, 7.6%-29.6%), 35.8% (95% CI, 26.2%-
47.6%), 45.9% (95% CI, 35.6%-57.5%), and 69.4% (95% CI,
Table 1. Demographic and Clinical Characteristics of Patients Included or
Excluded From the Final Cohort
No. (%) of Patients in Final Cohort
Included
(n = 260)
Excluded
(n = 69)
Sex
Male 178 (68.5) 51 (73.9)
Female 82 (31.5) 18 (26.1)
AF typea
Paroxysmal 168 (64.6) 36 (52.2)
Persistent 75 (28.8) 28 (40.6)
Permanent 17 (6.5) 3 (4.3)
Missing 0 2 (2.9)
Paroxysmal AF by fibrosis stageb
1 49 (18.8)
2 107 (41.2)
3 80 (30.8)
4 24 (9.2)
Coronary artery disease 26 (10.0) 4 (5.8)
Myocardial infarction 9 (3.5) 1 (1.5)
Tobacco use 23 (8.9) 5 (7.3)
Mitral valve disease 14 (5.4) 4 (5.8)
Hyperlipidemia 78 (30.0) 23 (33.3)
CHADS2
Congestive heart failure 15 (5.8) 2 (2.9)
Age >75 y 13 (5.0) 1 (1.5)
Hypertension (>160 mm Hg) 143 (55.0) 43 (62.3)
Diabetes mellitus 32 (12.3) 12 (17.4)
Prior stroke or TIA 13 (5.0) 6 (8.7)
Preablation antiarrhythmic drug
therapy
166 (63.9) 39 (56.5)
Abbreviations: AF, atrial fibrillation; TIA, transient ischemic attack.
a Paroxysmal defined as recurrent AF (2 episodes) that terminates
spontaneously within 7 days; persistent, recurrent AF that is sustained for
more than 7 days; permanent (or longstanding persistent AF), continuous AF
lasting longer than 1 year.14
b Stage 1 defined as fibrosis of less than 10% of the atrial wall; stage 2, 10% or
greater fibrosis but less than 20%; stage 3, 20% or greater fibrosis but less
than 30%; stage 4, fibrosis of 30% or greater.
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48.6%-87.7%), respectively. Figure 4 depicts the Kaplan-
Meier cumulative incidenceof arrhythmia recurrenceover the
follow-up period through 475 days after the blanking period.
Discussion
In the DECAAF multicenter, prospective, observational co-
hort study, noninvasive evaluation of left atrial fibrosis using
delayedenhancementMRIwas independentlyassociatedwith
procedural outcomes in patients undergoing AF ablation af-
teraccounting forknownbaselinecovariates.Astatistically sig-
nificant association between atrial fibrosis and history of hy-
pertension was also shown. The results from DECAAF were
obtained in a setting in which left atrial fibrosis was quanti-
fied using 3D delayed enhancement MRI from separate clini-
cal practices around the world and in which different abla-
tion approaches were used.
Toour knowledge, this study is the firstmulticenter study
to demonstrate the feasibility and potential clinical value of
delayedenhancementMRI in themanagementofpatientswith
AF considered for ablation. In current practice, criteria for se-
lecting goodcandidates forAFablation are limited. This study
contributes to the wide range of procedure success rates
reported.14 Because essentially all patients in the studypopu-
lation would be expected to have recurrent arrhythmia with-
out ablation treatment, the large variation in estimated recur-
renceprobabilitiesbetweenstages (rangingfrom15.3%forstage
1 to 69.4% for stage 4 at day475; Table 3) canbe interpreted as
characterizing a corresponding dependence in the probabil-
ity of ablation treatment failure on fibrosis. Hence, the de-
gree of left atrial wall fibrosis estimated by delayed enhance-
mentMRIhas thepotential tooffer anoninvasiveandeffective
method in determining which patients with AF are likely to
benefit from ablation while avoiding performing procedures
in patients likely to have arrhythmia recurrence.
The addition of atrial fibrosis to the arrhythmia recur-
rencepredictionmodel resulted ina statistically significant in-
crease in the C statistic compared with a traditional risk fac-
tormodel. TheC statistic valueof themodel including fibrosis
(0.69) closely approached0.70,which is the traditional cutoff
value used in statistical models.
Atrial Fibrosis and AF
Atrial fibrotic disease and AF are intertwined. Data from ani-
mal models and human studies show that AF leads to atrial
fibrosis.4,16 It is also known that atrial fibrosis is essential to
perpetuate atrial arrhythmias and leads to increased AF bur-
den as demonstrated in studies performed in experimental
models.17,18
The relationship between atrial fibrotic changes and AF
has recently been demonstrated in postmortem and open-
heart surgery histological analyses obtained from surgical
specimens.19,20 In these studies, the authors showed that
atrial tissue disease and fibrosis assessed from biopsy
obtained during open-heart surgery predicted postoperative
AF recurrence. Postmortem analysis of atrial tissue demon-
strated a correlation between atrial fibrosis and a history of
AF. In the same study, authors also demonstrated lack of sig-
nificant fibrosis in control patients of similar age with no his-
tory of AF. Previous retrospective analyses using delayed
enhancement MRI to assess the degree of atrial disease based
on fibrotic changes confirmed these findings. These analyses
also showed that every patient with AF possesses some
degree of atrial fibrotic changes that varies between minimal
and severe or extensive,12,13 including patients with lone AF.21
DECAAF confirmed these findings in a multicenter, prospec-
tive study.
The relationship between high blood pressure and AF is
well described.22,23 Systemic hypertension can lead to atrial
pressure and volume overload and subsequent atrial tissue
Table 2. Individual Demographic and Clinical Factors Related to
Arrhythmia Recurrence
Hazard Ratio (95% CI)a
P
Value
Female sex 1.46 (0.95-2.25) .08
Age at ablation per 10 y 1.05 (0.86-1.28) .61
AF typeb 1.22 (0.80-1.88) .36
Initial body mass index, per unit 1.03 (0.99-1.08) .11
History
Coronary artery disease 1.24 (0.64-2.39) .53
Congestive heart failure 1.45 (0.63-3.33) .37
Diabetes mellitus 1.24 (0.64-2.39) .53
Tobacco use 1.24 (0.64-2.39) .53
Mitral valve disease 3.45 (1.78-6.68) <.001
Hyperlipidemia 1.01 (0.64-1.58) .98
Stroke 0.81 (0.26-2.57) .73
CHADS2 score
1 vs 0 1.13 (0.70-1.82) .63
2 vs 0 1.17 (0.63-2.17) .62
3 vs 0 1.27 (0.39-4.15) .69
4 vs 0 2.83 (0.86-9.26) .09
Congestive heart failure 0.82 (0.30-2.24) .70
Age >75 y 1.19 (0.48-2.93) .71
Hypertension (>160 mm Hg) 1.36 (0.88-2.09) .16
Diabetes mellitus 1.33 (0.72-2.44) .37
Prior stroke or TIA 1.19 (0.48-2.92) .71
Antiarrhythmic drug therapy 0.87 (0.56-1.33) .51
Left atrial volume (per 10 mL) 1.05 (1.00-1.09) .05
LVEF per 1% 1.02 (0.99-1.05) .16
Catheter type
Radiofrequency 1 [Reference]
.73
Cryo 0.85 (0.35-2.10)
Ablation type
Pulmonary vein isolation 1 [Reference]
.57
Other 1.14 (0.73-1.77)
Arrhythmia recurrence per 1% increase
in left atrial fibrosis 1.06 (1.03-1.08) <.001
Abbreviations: LVEF, left ventricular ejection fraction; TIA, transient ischemic
attack.
a The hazard ratios relate to the time of atrial fibrillation recurrence by day 325,
individual demographic and clinical factors, and percent fibrosis based on
separate univariable Cox regression analyses.
b Persistent or permanent vs paroxysmal.
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change. In DECAAF, hypertension was the only baseline fac-
tor associatedwith atrial fibrosis in patients with AF. None of
the known AF risk factors, including the composite CHADS2
score, predicted fibrosis burden. This possibly could be ac-
counted for by the relatively younger AF patient population
enrolled in DECAAF (mean [SD] age, 59.1 [10.7] years) and the
low prevalence of significant comorbidities in these patients.
Nevertheless, the DECAAF population seems to be represen-
tative of the AF ablation population.24,25
Current clinical practice evaluates AF using a classifica-
tion system that describes the pattern of arrhythmia and
need for treatment, including electrical and chemical
cardioversion.14 Patient comorbidities including echocardio-
graphic evaluation of atrial size and ventricular function also
play a role in formulating an overall prediction in response to
treatment.26,27 It was recently demonstrated that AF clinical
phenotypeandAF-related fibrotic changesoratrialdiseasepro-
gression are not interchangeable or equivalent. For example,
patients with a short known history of paroxysmal AF could
have extensive atrial fibrosis and conversely patients diag-
nosed with persistent AF for many years could have a mini-
mal amountof fibrosis.Until data fromrecentpublications12,13
becameavailable, therewasno insight intotheunderlyingatrial
fibrosis associatedwithdifferent phenotypes ofAF. Theweak
correlation between the temporal pattern of AF anddegree of
fibrosis was confirmed in DECAAF.
Ablation Outcome for AF
Since the introduction of catheter ablation as a viable treat-
ment option for AF more than a decade ago, reported long-
term procedural success in suppressing AF has ranged be-
tween 20% and 50%.14 Although both procedure time and
safety have improved substantially, the success rate has not
seen a concomitantmeaningful improvement despite signifi-
cant advancement in the technology used in the ablation
procedure.28 Another major challenge facing the AF ablation
approach is the need for repeat ablations,14,29 with some pa-
tients requiring up to 4 interventional procedures to achieve
suppressionof recurrent arrhythmias.30 In aprospective, ran-
domized, multicenter study comparing ablation with antiar-
rhythmic drug therapy, it was demonstrated that 66% of pa-
tients had better health outcomes due to ablative treatment
of paroxysmal AF after 9 months of follow-up.31 Most of the
published ablation studies, similar to this one, are short-term
(≤1 year) follow-up reports.32,33 Longer follow-up suggests a
lower success rate.34,35
A recent report19 described the effect of atrial fibrosis on
surgical AF ablation outcome in an open-heart surgery
Figure 3. Relationship of Atrial Fibrillation RecurrenceWith Percent
Fibrosis
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Adjusted for age, sex, hypertension, congestive heart failure, mitral valve
disease, diabetes, atrial fibrillation type (paroxysmal or persistent), left atrial
volume, left ventricular ejection fraction, and participating center (model 5)
based on a cubic spline analysis with follow-up censored at day 325 after the
blanking period. The strength of the association was greater at lower levels of
fibrosis than at higher levels (P = .03 for test of nonlinearity). Blue dashed lines
indicate 95% CI.
Table 3. Absolute Arrhythmia Risk at 325 and 475 Days After Blanking
Period
Stage
Absolute Risk (95% CI) by
No. of Days After 90-d Blanking Period
325 d 475 d
Without covariate adjustmenta
1 0.15 (0.08-0.30) 0.15 (0.08-0.30)
2 0.33 (0.24-0.43) 0.36 (0.26-0.48)
3 0.46 (0.36-0.58) 0.46 (0.36-0.58)
4 0.51 (0.33-0.72) 0.69 (0.49-0.88)
With covariate adjustmentb
1 0.12 (0.03-0.21) 0.14 (0.03-0.23)
2 0.31 (0.21-0.39) 0.36 (0.25-0.48)
3 0.45 (0.33-0.55) 0.49 (0.35-0.60)
4 0.55 (0.28-0.71) 0.65 (0.39-0.80)
a The absolute risk was calculated using the Kaplan-Meier method and the 95%
confidence interval was based on survival estimate at the log-log scale.
b The absolute risk was calculated based on the Cox proportional hazardmodel
and baseline hazard was obtained using the Breslow estimator. All covariates
in model 5 (see Statistical Methods section of text for definition of model 5)
were used for the adjustment. Mean values for each of the covariates were
used to calculate adjusted absolute risks.
Figure 4. Cumulative Incidence of Arrhythmia RecurrenceWithout
Covariate Adjustment Through Day 475 After the Blanking Period
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patient series. Kainuma et al19 described a correlation
between procedural failures and progressive atrial disease
and fibrosis evaluated from biopsies taken during surgery.
These and other studies highlight the fact that ablation
therapy may not be the optimal treatment option for all AF
patients. Therefore, it would be clinically useful if patients
likely to respond could be identified and selected for abla-
tion while other patients not likely to respond to ablation
could be counseled against this procedure. The DECAAF
study demonstrates the feasibility and potential clinical
value of such a concept by evaluating atrial fibrosis nonin-
vasively using MRI prior to the ablation procedure in a mul-
ticenter setting.
The consensus document14 published in 2012 did not
dictate a specific energy source or ablation approach to treat
AF; the decision is left to the discretion of the physician per-
forming the procedure. The same model was adopted for
DECAAF. Despite the various ablation approaches and
energy sources applied in the DECAAF study population,
atrial fibrosis remained associated with procedural out-
come. The feasibility of implementing delayed enhance-
ment MRI screening to detect left atrial fibrosis into clinical
practice could potentially improve patient selection for AF
ablation and could translate into cost-savings by avoiding
unnecessary AF ablation procedures.36 Individualizing the
type of invasive treatment for AF based on the association
between fibrosis and arrhythmia recurrence merit further
investigation in future studies aimed at demonstrating that
exclusion of patients with extensive fibrosis leads to
improved procedural outcomes.
Study Limitations
Theexclusionof 17.3%(n = 57patients) of the initial cohortwas
attributed to poor quality of delayed enhancementMR images
due tovarying levels of cardiacMRI expertise at theparticipat-
ing centers. Upon further analysis of the nondiagnostic im-
ages, it was found that 63.2% (n = 36) of the poor quality im-
ages were due to MRI technologist error, 29.8% (n = 17) were
related to individual patients (arrhythmia, fast heart rate [>120
beats/min]), irregular respiration, and high bodymass index),
and the remaining 7.0% (n = 4) were due to hardware limita-
tions.Knowing these reasons forpoor imagequality couldhelp
to improve image acquisition in future studies. Although the
study demonstrated an association between atrial fibrosis and
arrhythmiarecurrencefollowingablation, itdidnotprovideevi-
dence of an effect of testing on clinical outcomes.
Conclusions
TheDECAAFmulticenter,prospectivestudydemonstratedthat
amongpatientswith atrial fibrillationundergoing catheter ab-
lation, atrial fibrosis estimated by delayed enhancementMRI
was independently associatedwith likelihoodof recurrent ar-
rhythmia. The clinical implications of this association war-
rant further investigation.
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